GS vs LAB · P/E 20, $324.25B cap vs rev $174.4M
Goldman Sachs Group Inc (GS) versus Standard Biotools Inc (LAB) — a side-by-side from cached financials, not a winner call.
Goldman Sachs Group Inc (GS) is a capital markets company listed on NYSE. It is led by David Solomon.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
GS does not have a complete income-statement cache yet.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
GS currently screens at market cap $324.25B and trailing P/E 20.1. LAB currently screens at market cap $317.1M.
Not investment advice. Open the GS and LAB stock pages for the full models.
Not investment advice.